Lenacapavir: Market Analysis of the First-in-Class Capsid Inhibitor 2023-10-13
In August 2022, Gilead announced that the European Commission (EC) has granted marketing authorization for Sunlenca (Lenacapavir), an innovative treatment for adults with multi-drug resistant HIV infection. The treatment works in combination with other antiretroviral(s) when it isn't
Read More